<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Angiodynamics Inc — News on 6ix</title>
<link>https://6ix.com/company/angiodynamics-inc</link>
<description>Latest news and press releases for Angiodynamics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 02 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/angiodynamics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835465d78dffbe2df0e2f47.webp</url>
<title>Angiodynamics Inc</title>
<link>https://6ix.com/company/angiodynamics-inc</link>
</image>
<item>
<title>AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability</title>
<link>https://6ix.com/company/angiodynamics-inc/news/angiodynamics-reports-fiscal-year-2026-third-quarter-financial-results-sustained-double-digit-med-tech-growth-drives-continued-profitability-10</link>
<guid isPermaLink="true">https://6ix.com/company/angiodynamics-inc/news/angiodynamics-reports-fiscal-year-2026-third-quarter-financial-results-sustained-double-digit-med-tech-growth-drives-continued-profitability-10</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Med Tech segment delivered its sixth consecutive quarter of double-digit growth Strong adjusted EBITDA Third consecutive quarter the Company raised full year</description>
</item>
<item>
<title>AngioDynamics to Present at the 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/angiodynamics-inc/news/angiodynamics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/angiodynamics-inc/news/angiodynamics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Tue, 31 Mar 2026 12:00:00 GMT</pubDate>
<description>LATHAM, N.Y., March 31, 2026--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the management team will present at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026. The Company's presentation will begin at 8:45 a.m. (ET).</description>
</item>
<item>
<title>AngioDynamics to Report Fiscal 2026 Third Quarter Results on April 2, 2026</title>
<link>https://6ix.com/company/angiodynamics-inc/news/angiodynamics-to-report-fiscal-2026-third-quarter-results-on-april-2-2026</link>
<guid isPermaLink="true">https://6ix.com/company/angiodynamics-inc/news/angiodynamics-to-report-fiscal-2026-third-quarter-results-on-april-2-2026</guid>
<pubDate>Thu, 19 Mar 2026 12:00:00 GMT</pubDate>
<description>LATHAM, N.Y., March 19, 2026--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2026 before the market open on Thursday, April 2, 2026. The Company’s management will host a conference call at 8:00 am ET the same day to dis</description>
</item>
<item>
<title>AngioDynamics to Present at the Leerink Partners Global Healthcare Conference</title>
<link>https://6ix.com/company/angiodynamics-inc/news/angiodynamics-to-present-at-the-leerink-partners-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/angiodynamics-inc/news/angiodynamics-to-present-at-the-leerink-partners-global-healthcare-conference</guid>
<pubDate>Mon, 23 Feb 2026 21:30:00 GMT</pubDate>
<description>LATHAM, N.Y., February 23, 2026--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced, that Jim Clemmer, President and Chief Executive Officer, will present at the Leerink Partners Global Healthcare Conference on Monday, Mar. 9, 2026. The Company's presentation will begin at 1:40 p.m. (ET).</description>
</item>
<item>
<title>AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform</title>
<link>https://6ix.com/company/angiodynamics-inc/news/angiodynamics-expands-indications-for-the-nanoknife-system-across-europe-strengthening-multi-organ-tumor-ablation-platform</link>
<guid isPermaLink="true">https://6ix.com/company/angiodynamics-inc/news/angiodynamics-expands-indications-for-the-nanoknife-system-across-europe-strengthening-multi-organ-tumor-ablation-platform</guid>
<pubDate>Thu, 19 Feb 2026 13:30:00 GMT</pubDate>
<description>LATHAM, N.Y., February 19, 2026--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced expanded European indications for its NanoKnife System to include soft tissue ablation for tumors of the liver, pancreas, kidney, and prostate, including in patients with intermediate-risk prostate cancer.</description>
</item>
<item>
<title>AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care</title>
<link>https://6ix.com/company/angiodynamics-inc/news/angiodynamics-and-pert-consortiumr-launch-investigator-led-research-fund-advance</link>
<guid isPermaLink="true">https://6ix.com/company/angiodynamics-inc/news/angiodynamics-and-pert-consortiumr-launch-investigator-led-research-fund-advance</guid>
<pubDate>Thu, 05 Feb 2026 05:00:00 GMT</pubDate>
<description>The ALPHA-PE Research Fund Supports Independent, Physician-Led Studies to Advance Real-World PE Evidence LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc.</description>
</item>
<item>
<title>AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance</title>
<link>https://6ix.com/company/angiodynamics-inc/news/angiodynamics-convene-cardiovascular-leaders-scientific-forum-pipeline-continues</link>
<guid isPermaLink="true">https://6ix.com/company/angiodynamics-inc/news/angiodynamics-convene-cardiovascular-leaders-scientific-forum-pipeline-continues</guid>
<pubDate>Tue, 03 Feb 2026 05:00:00 GMT</pubDate>
<description>Physician-led Collaboration Reinforces Ongoing Regulatory Activity and Clinical Advancement Across the Cardiovascular Portfolio LATHAM, N.Y.--(BUSINESS</description>
</item>
<item>
<title>AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability</title>
<link>https://6ix.com/company/angiodynamics-inc/news/angiodynamics-reports-fiscal-year-2026-second-quarter-financial-results-continued</link>
<guid isPermaLink="true">https://6ix.com/company/angiodynamics-inc/news/angiodynamics-reports-fiscal-year-2026-second-quarter-financial-results-continued</guid>
<pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
<description>Med Tech segment delivers fifth consecutive quarter of double-digit growth Strong adjusted EBITDA; and positive cash flow Three regulatory milestones support</description>
</item>
<item>
<title>AngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026</title>
<link>https://6ix.com/company/angiodynamics-inc/news/angiodynamics-report-fiscal-2026-second-quarter-results-january-6-2026-2025-12-23</link>
<guid isPermaLink="true">https://6ix.com/company/angiodynamics-inc/news/angiodynamics-report-fiscal-2026-second-quarter-results-january-6-2026-2025-12-23</guid>
<pubDate>Tue, 23 Dec 2025 05:00:00 GMT</pubDate>
<description>LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy</description>
</item>
<item>
<title>AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/angiodynamics-inc/news/angiodynamics-present-44th-annual-jp-morgan-healthcare-conference-2025-12-22</link>
<guid isPermaLink="true">https://6ix.com/company/angiodynamics-inc/news/angiodynamics-present-44th-annual-jp-morgan-healthcare-conference-2025-12-22</guid>
<pubDate>Mon, 22 Dec 2025 05:00:00 GMT</pubDate>
<description>LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's</description>
</item>
<item>
<title>AngioDynamics to Participate in the UBS Global Healthcare Conference</title>
<link>https://6ix.com/company/angiodynamics-inc/news/angiodynamics-participate-ubs-global-healthcare-conference-2025-10-27</link>
<guid isPermaLink="true">https://6ix.com/company/angiodynamics-inc/news/angiodynamics-participate-ubs-global-healthcare-conference-2025-10-27</guid>
<pubDate>Mon, 27 Oct 2025 04:00:00 GMT</pubDate>
<description>LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's</description>
</item>
<item>
<title>AngioDynamics’ NanoKnife® System Named to TIME’s 2025 Best Inventions List</title>
<link>https://6ix.com/company/angiodynamics-inc/news/angiodynamics-nanoknifer-system-named-times-2025-best-inventions-list-2025-10-13</link>
<guid isPermaLink="true">https://6ix.com/company/angiodynamics-inc/news/angiodynamics-nanoknifer-system-named-times-2025-best-inventions-list-2025-10-13</guid>
<pubDate>Mon, 13 Oct 2025 04:00:00 GMT</pubDate>
<description>Function-Preserving Therapy Recognized in the Medical Devices Category for its Use of Irreversible Electroporation (IRE) Technology in Treatment of Prostate</description>
</item>
<item>
<title>AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum</title>
<link>https://6ix.com/company/angiodynamics-inc/news/angiodynamics-reports-fiscal-year-2026-first-quarter-financial-results-med-tech</link>
<guid isPermaLink="true">https://6ix.com/company/angiodynamics-inc/news/angiodynamics-reports-fiscal-year-2026-first-quarter-financial-results-med-tech</guid>
<pubDate>Thu, 02 Oct 2025 04:00:00 GMT</pubDate>
<description>Med Tech segment delivers fourth consecutive quarter of over 20% revenue growth Reported Adjusted EBITDA of $2.2 million compared to ($0.2) million in the</description>
</item>
<item>
<title>AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025</title>
<link>https://6ix.com/company/angiodynamics-inc/news/angiodynamics-report-fiscal-2026-first-quarter-results-october-2-2025-2025-09-18</link>
<guid isPermaLink="true">https://6ix.com/company/angiodynamics-inc/news/angiodynamics-report-fiscal-2026-first-quarter-results-october-2-2025-2025-09-18</guid>
<pubDate>Thu, 18 Sep 2025 04:00:00 GMT</pubDate>
<description>LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy</description>
</item>
<item>
<title>AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference</title>
<link>https://6ix.com/company/angiodynamics-inc/news/angiodynamics-present-canaccord-genuity-45th-annual-growth-conference-2025-08-06</link>
<guid isPermaLink="true">https://6ix.com/company/angiodynamics-inc/news/angiodynamics-present-canaccord-genuity-45th-annual-growth-conference-2025-08-06</guid>
<pubDate>Wed, 06 Aug 2025 04:00:00 GMT</pubDate>
<description>LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy</description>
</item>
<item>
<title>AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia</title>
<link>https://6ix.com/company/angiodynamics-inc/news/angiodynamics-enrolls-first-patient-ambition-btk-trial-advancing-treatment-critical</link>
<guid isPermaLink="true">https://6ix.com/company/angiodynamics-inc/news/angiodynamics-enrolls-first-patient-ambition-btk-trial-advancing-treatment-critical</guid>
<pubDate>Mon, 28 Jul 2025 04:00:00 GMT</pubDate>
<description>Trial Investigates Use of Auryon Atherectomy System in Cases with Challenging Below-the-Knee Blockages LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc.</description>
</item>
<item>
<title>AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology</title>
<link>https://6ix.com/company/angiodynamics-inc/news/angiodynamics-announces-publication-preserve-study-nanoknifer-system-prostate-tissue</link>
<guid isPermaLink="true">https://6ix.com/company/angiodynamics-inc/news/angiodynamics-announces-publication-preserve-study-nanoknifer-system-prostate-tissue</guid>
<pubDate>Wed, 23 Jul 2025 04:00:00 GMT</pubDate>
<description>Peer-reviewed findings demonstrate high disease control and quality-of-life preservation, supporting shift toward focal therapy in prostate treatment LATHAM,</description>
</item>
<item>
<title>AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth</title>
<link>https://6ix.com/company/angiodynamics-inc/news/angiodynamics-reports-strong-fiscal-year-2025-fourth-quarter-and-full-year-financial</link>
<guid isPermaLink="true">https://6ix.com/company/angiodynamics-inc/news/angiodynamics-reports-strong-fiscal-year-2025-fourth-quarter-and-full-year-financial</guid>
<pubDate>Tue, 15 Jul 2025 04:00:00 GMT</pubDate>
<description>Med Tech franchise delivers third consecutive quarter of over 20% revenue growth Reported strong adjusted EBITDA in the fourth quarter resulting in positive</description>
</item>
<item>
<title>AngioDynamics to Report Fiscal 2025 Fourth Quarter and Full-Year Financial Results on Tuesday, July 15, 2025</title>
<link>https://6ix.com/company/angiodynamics-inc/news/angiodynamics-report-fiscal-2025-fourth-quarter-and-full-year-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/angiodynamics-inc/news/angiodynamics-report-fiscal-2025-fourth-quarter-and-full-year-financial-results</guid>
<pubDate>Mon, 07 Jul 2025 04:00:00 GMT</pubDate>
<description>LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy</description>
</item>
<item>
<title>AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F1885 System for Treatment of Acute Pulmonary Embolism</title>
<link>https://6ix.com/company/angiodynamics-inc/news/angiodynamics-announces-first-patient-enrolled-120000922</link>
<guid isPermaLink="true">https://6ix.com/company/angiodynamics-inc/news/angiodynamics-announces-first-patient-enrolled-120000922</guid>
<pubDate>Mon, 23 Jun 2025 12:00:00 GMT</pubDate>
<description>LATHAM, N.Y., June 23, 2025--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving patient quality of life, today announced the first patient has been enrolled in the RECOVER-AV clinical trial, a prospective, multi-center, multi-national, single-arm study evaluating the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System in the</description>
</item>
</channel>
</rss>